Results 171 to 180 of about 125,716 (297)

Potential utility of l-carnitine for preventing liver tumors derived from metabolic dysfunction–associated steatohepatitis

Junyan Lyu, Hikari Okada, Hajime Sunagozaka, Kazunori Kawaguchi, Tetsuro Shimakami, Kouki Nio, Kazuhisa Murai, Takayoshi Shirasaki, Mika Yoshida, Kuniaki Arai, Tatsuya Yamashita, Takuji Tanaka, Kenichi Harada, Toshinari Takamura, Shuichi Kaneko, Taro Yamashita, Masao Honda   +16 more
openalex   +1 more source

Berberine Reduces Neurotoxicity Related to Nonalcoholic Steatohepatitis in Rats [PDF]

, 2015
Doaa A. Ghareeb, Sofia Khalil, Hani S. Hafez, Jürgen Bajorath, Hany E. A. Ahmed, Eman Sarhan, Eiman Elwakeel, Maha El Demellawy   +7 more
openalex   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease After Hepatitis C Virus Cure

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Hepatitis C virus (HCV) infection is an infectious disease carrying a high risk of metabolic disorders. Chronic HCV (CHC) patients can possess extrahepatic manifestations such as diabetes, steatotic liver disease (SLD), and other metabolic alterations.
Chung‐Feng Huang, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang   +3 more
wiley   +1 more source

TRIB3 Is a Hub Gene in Steatohepatitis and Aggravates Lipid Deposition and Inflammation in Hepatocytes

Diabetes, Metabolic Syndrome and Obesity
Wen Xia,1,* Li Xiao,1,* Huan Cheng,1 Yuwei Feng2 1Department of Cardiovascular Medicine, Wuhan No.1 Hospital, Wuhan, Hubei, People’s Republic of China; 2Department of Hepatology with Integrated Traditional Chinese and Western Medicine, Hubei No.3
Xia W, Xiao L, Cheng H, Feng Y
doaj  

Targeting SPHK1 by 8-HETrE attenuates MASH-Driven fibrosis via restoration of hepatic stellate cell mitochondrial dynamics. [PDF]

Cell Biol Toxicol
Chen S, Li J, Xu K, Wen J, Zhang F, Zhuge Y, Wang L, Yi Y, Zhang H, Zhang W.   +9 more
europepmc   +1 more source

Effect of pentoxifylline on histological activity and fibrosis of nonalcoholic steatohepatitis patients: A one year randomized control trial [PDF]

, 2017
Shahinul Alam, SKM Nazmul Hasan, Golam Mustafa, Mahabubul Alam, Mohammad Amjad Kamal, Nooruddin Ahmad   +5 more
openalex   +1 more source

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

The Lancet, 2019
Z. Younossi, V. Ratziu, R. Loomba, M. Rinella, Q. Anstee, Z. Goodman, P. Bedossa, A. Geier, S. Beckebaum, P. Newsome, D. Sheridan, M. Sheikh, J. Trotter, W. Knapple, E. Lawitz, M. Abdelmalek, K. Kowdley, A. Montaño-Loza, J. Boursier, P. Mathurin, E. Bugianesi, G. Mazzella, A. Olveira, H. Cortez‐Pinto, I. Graupera, D. Orr, L. Gluud, J. Dufour, D. Shapiro, J. Campagna, L. Zaru, L. Macconell, R. Shringarpure, S. Harrison, A. Sanyal   +34 more
semanticscholar   +1 more source

Beyond the Green Light: Evaluating the Uncertainties of Resmetirom for Non-Cirrhotic Nonalcoholic Steatohepatitis Treatment. [PDF]

Health Sci Rep
Sajid HMM, Rahman F, Mahmoud A.
europepmc   +1 more source

NON-INVASIVE DIAGNOSTIC APPROACHES IN METABOLIC-RELATED STEATOHEPATITIS

Mamajonov Islombek Sardorbek ugli, Yaminova Nafisa Khaydaraliyevna   +1 more
openalex   +1 more source

Correction: Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model <i>in vivo</i>. [PDF]

Front Pharmacol
Li H, Xi Y, Xin X, Feng Q, Hu Y.
europepmc   +1 more source